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Abstract
Background Intensive insulin therapy to maintain normoglycemia after cardiac sur-
gery reduces morbidity and mortality. We investigated the magnitude and dura-
tion of hyperglycemia caused by dexamethasone administered after cardiopul-
monary bypass.
Methods A single-center before-after cohort study was performed. All consecutive
patients undergoing coronary artery bypass grafting with cardiopulmonary by-
pass during a 6-month period were included. Insulin administration was guided
by a sliding scale protocol. Halfway the observation period, the dexamethasone
protocol was changed. The single dose (1D) group received a pre-operative
dose of dexamethasone of 1 mg/kg. The double dose group (2D) received an
additional dose of 0.5 mg/kg of dexamethasone post-operatively at ICU admis-
sion.
Results We included 116 patients in the 1D group and 158 patients in the 2D group.
There were no significant baseline differences between the groups. Median Eu-
roscore was 5. In univariable analysis, the glucose level was different between
groups 1D and 2D at 4, 6, 9, 12 and 24 hours after ICU admission (all P<0.001).
Insulin infusion was higher in the 1D group. Corrected for insulin dose in multi-
variable linear analysis, the difference in glucose between the 1D and 2D groups
was 1.5 mmol/L (95% confidence interval 1.0-2.0, P<0.001) 12 hours after ICU
admission.
Conclusions Dexamethasone exerts a hyperglycemic effect in cardiac surgery pa-
tients. Patients receiving high-dose corticosteroid therapy should be monitored
and treated more intensively for hyperglycemic episodes.
Background
Cardiac surgery with cardiopulmonary bypass induces a strong systemic inflamma-
tory response in previously healthy individuals.1 This response is characterized by
changes in cardiovascular and pulmonary function.2–4 Corticosteroids inhibit this in-
flammatory response and may thus ameliorate the adverse effects of cardiopulmonary
bypass.1,5,6 High-dose dexamethasone is one of the therapies given in some centers
to reach this effect. However, corticosteroid use in cardiac surgery is controversial,
because important side effects may result.7 One of the side effects is increased insulin
resistance, which causes hyperglycemia.8 The emerging evidence on negative effects
of dexamethasone has prompted a protocol change in our institution.
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In patients with myocardial infarction, prolonged hyperglycemia after admission
is associated with adverse outcome.9,10 Glycometabolic dysregulation is common in
patients undergoing cardiac surgery.11 Tight glucose control with intensive insulin
therapy has been shown to decrease mortality and morbidity in these patients.12 In
patients undergoing coronary artery bypass grafting, the survival benefit persisted
at 4 years follow-up.13 As the benefits of insulin therapy are related to the level of
achieved glucose control, the impact of corticosteroids on hyperglycemia has become
more relevant.14 We hypothesized that a reduction of dexamethasone dose would
facilitate glucose control. We performed a before-after study to quantify the hyper-
glycemic effect of a second dose of dexamethasone administered post-operatively at
the intensive care unit (ICU) in patients undergoing coronary artery bypass surgery
(CABG) with cardiopulmonary bypass.
Methods
This study was performed at a 14-bed thoracic ICU in a tertiary teaching hospital.
During a 6 month period (from April to October 2005) all patients undergoing CABG
with the use of cardiopulmonary bypass were studied. Both patients with only CABG
and CABG with additional valve repair were included. During the 6-month obser-
vation period, the treatment protocol was modified by the medical staff. Before the
change, all patients were administered 1.0 mg of dexamethasone per kilogram of
body weight at the induction of anesthesia and a second dose of 0.5 mg/kg at ad-
mission to the ICU. The patients in this dosing scheme were in the double-dose (2D)
group. After the change, the second dose was withheld, so patients only received the
initial 1.0 mg/kg dose (group 1D). The protocol change was made after a previous
study, in which high-dose dexamethasone failed to provide a beneficial effect on peri-
operative renal function15 and review of other available evidence.7 The institutional
review board approved this study.
At baseline, we collected demographic and clinical information, including sex,
age, body mass index (BMI) and presence of diabetes before hospital admission. Op-
erative risk stratification was done by means of the EuroSCORE model.16 Time on
cardiopulmonary bypass and total operation time were recorded. During the ICU stay,
we collected blood glucose levels, and insulin administration for the first 48 hours.
Glucose levels were measured in arterial blood samples using a point-of-care blood
gas analyzer present at the ICU (ABL Radiometer 700 series, Copenhagen). Insulin
was administered according to a sliding-scale insulin dosing algorithm. The algorithm
was designed to treat hyperglycemia defined as a glucose level over 10 mmol/L but
did not aim for normoglycemia (4.4 − 6.1 mmol/L). Our protocol prescribed a 1 liter
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infusion of glucose 5% during the first 24 hours.
For data processing and statistical analysis SPSS version 12.0 was used. Baseline
characteristics of the two groups were expressed as mean ± standard deviation (SD)
for normally distributed variables or as median (interquartile range, IQR) for other
variables. We compared differences between groups with the Student’s t-test for nor-
mal distributed variables or the Mann-Whitney U test for other continuous variables.
For categorical variables, the Chi-square test or Fisher’s exact test were used when
appropriate. We analyzed the blood glucose levels at 2, 4, 6, 9, 12, 24 and 48 hours
after ICU admission for each patient. The glucose values at these specific times were
calculated by linear interpolation. We also calculated the hyperglycemic index for the
first 12 hours after admission.17
The time course of glucose levels was compared with univariable analysis be-
tween groups 1D and 2D to determine if and when glucose levels diverged between
the two groups. It was then determined at what time the difference in glucose was
greatest between the two groups. To assess the relative contributions of patient group
(1D or 2D), age, sex, diabetes, BMI and insulin administration to this maximum differ-
ence in glucose, we performed multivariable linear regression analysis. We included
variables in the model that had a univariable P value smaller than 0.15. Differences
or statistical relations with a P value of less than 0.05 were considered significant.
Bonferroni’s correction for multiple testing was applied where appropriate.
Table 4.1: Patient characteristics
1D group 2D group P value
N 116 158
Male sex 84 (72%) 108 (68%) ns
Age (years) 68 ± 10 69 ± 8 ns
Diabetes mellitus 33 (28%) 36 (23%) ns
Body mass index 27.4 ± 3.4 27.6 ± 3.9 ns
EuroSCORE 5 (2 - 7) 5 (3 - 7) ns
Other than isolated CABG 32 (28%) 33 (21%) ns
Emergency procedure 3 (3%) 7 (5%) ns
Number of anastomoses 3 (2 - 4) 3 (2 - 4) ns
Time on CPB (hours) 1.8 (1.3 - 2.7) 1.6 (1.4 - 2.3) ns
Operation time (hours) 5.5 (4.6 - 6.4) 5.0 (4.3 - 5.9) 0.01
30-day mortality 3 (2.6%) 6 (3.8%) ns
Characteristics of the two patient groups. 1D: single dose group, 2D: double dose group. Values
are mean ± standard deviation or median (IQR). CPB: cardiopulmonary bypass.
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Results
A total of 274 patients were included in this study, 116 in the 1D-group and 158
patients in the 2D-group. Table 1 shows the patient characteristics at baseline for both
groups. The mean age of the population was 69 ± 9 years, and 70% of them were
male. Median ICU length of stay was 1.0 (0.8-1.8) days and the hospital length of
stay was 12 (9-16) days. Pre-operative risk scoring shows that 36% of the population
was at medium risk (EuroSCORE 3-5), and 42% was at high risk (EuroSCORE>5).
Thirty-day all cause mortality was 3.3%. The operation time was slightly longer in
the 1D group.
Figure 4.1: Time course of glucose levels after ICU admission
Comparison of post-cardiac surgery hyperglycemia for the single dose group (1D group,
triangles, 116 patients) and for the double dose group (2D group, circles, 158 patients). Data are
medians and interquartile ranges. The glucose level was higher at 4, 6, 9, 12, and 24 hours in
the 2D group (all P<0.001, after Bonferroni correction for multiple testing). The difference was
largest at 12 hours after ICU admission.
Figure 1 shows the mean and standard deviation of blood glucose levels over
the first 48 hours after ICU admission. At 4, 6, 9, 12 and 24 hours after admission
glucose levels were significantly lower in the 1D-group than in the 2D-group, with
the greatest difference at 12 hours. The hyperglycemic index over the first 12 hours
was significantly lower in the 1D group: 3.5 ± 1.4 mmol/L vs. 4.7 ± 1.7 mmol/L
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(P<0.001). Performance and attention for the glucose control protocol improved
during the study period. Patients in the 1D group received 26 (15 - 36) units of
insulin during the first 12 hours of ICU stay, for the 2D group this was 12 (0 - 27.25,
P<0.001). The number of glucose measurements in the first 12 hours was 6 (4 - 7) in
the 1D group and 4 (3 - 5) in the 2D group. Figure 2 shows the glucose level 12 hours
Figure 4.2: Glucose levels at 12 hours post ICU admission stratified for mean insulin dose before
that time
White bars represent the 1D group, gray bars represent the 2D group.
after admission for both groups stratified for mean insulin infusion rate during the
first 12 hours. In multivariable linear regression analysis, the attributable increase of
glucose at 12 h after admission was 1.5 mmol/L for a second dose of dexamethasone
(P<0.001, table 2). The difference in glucose levels between the 1D and 2D groups
was similar in patients with and without a history of diabetes.
Discussion
In this study we found that cardiac surgical patients who received two doses of dex-
amethasone displayed higher blood glucose levels between 6 and 24 hours after ICU
admission than patients who received one dose of dexamethasone.
High dose dexamethasone is a controversial therapy in cardiac surgery patients.
Both studies that favor the use of corticosteroids5 or studies that show some bene-
fit6 as well as studies that show no benefit7,15,18 have been published. The effect of
steroids on glucose control may be of interest, because high glucose levels are com-
48
Dexamethasone and glucose control after cardiac surgery





Age (per year) 0.04 (0.01 to 0.07)+ 0.05 (0.03 to 0.07)+
Male sex ns
History of diabetes ns
Body mass index ns
Other than isolated
CABG
-0.63 (-1.25 to -0.01)∗ ns
Emergency procedure ns
EuroSCORE ns
Time on CPB -0.51 (-0.83 to -0.19)+ ns
Operation time -0.32 (-0.51 to -0.13)+ ns
Insulin in the first 12
hours (units) -0.033 (-0.045 to -0.021)
+ -0.024 (-0.036 to -0.012)+
2D vs 1D group 1.8 (1.3 to 2.3)+ 1.5 (1.0 to 2.0)+
Parameters in the linear model predicting glucose level 12 hours after admission. CI: confidence
interval. *:P<0.05. +:P<0.001.
mon and have been shown to be independent predictors of adverse outcome during
cardiac surgery.11,19 Treatment of hyperglycemia by continuous insulin infusion has
recently been shown to improve outcome.12,13,20 The difference of 1.5 mmol/L in
glucose levels we found in multivariable analysis is clinically relevant considering a
post-hoc analysis found that the odds ratio for ICU mortality for every increase in glu-
cose level of 1.1 mmol/L is 1.3.14 Our study was not powered to detect a difference
in mortality.
While the merit of steroids for cardiopulmonary bypass may be disputed, steroids
are administered for many other indications in other critically ill patients. For in-
stance, lower dose corticosteroids may be used to prevent atrial fibrillation after car-
diac surgery.21 For other patient categories, effects on glucose control have recently
been shown for hydrocortisone in patients with septic shock,22 or for dexamethasone
against nausea in abdominal surgery patients.23
A number of limitations of our study must be mentioned. First, we had not im-
plemented a tight glucose control protocol at the thoracic ICU at the time of this
study. Therefore, overall glucose control was not comparable to the levels achieved
in intervention studies, reflected by the HGI which indicates mean glucose levels of
9.5 and 10.7 mmol/L for the groups respectively. We think this does not change our
conclusion that dexamethasone induces hyperglycemia, as we hypothesize that under
a tight glucose control protocol, we would have found that the 1D group would re-
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quire less interventions and lower doses of insulin than the 2D group to achieve the
same glucose targets. Second, although data collection was prospective, the study as
a whole must be regarded as a retrospective study. Bias could have been introduced
in our data in a number of ways. Inherent to the before-after design the patients were
not randomly allocated to the two dosing groups. A very important variable, insulin
infusion, was found to be significantly different between the two groups. The multi-
variable analysis incorporating this and other possible confounding factors confirmed
the highly significant relation of glucose levels with the administration of one or two
dexamethasone doses. This analysis may still overestimate the difference caused by
dexamethasone due to unknown confounding factors and due to non-linear effects of
the included variables. Not all cardiac surgery centers use dexamethasone as routine
treatment in all cardiac surgery patients. This may be a limitation to the relevance of
our study. However, it is unlikely that the hyperglycemic effect we measured in this
study is unique to dexamethasone or cardiac surgery patients. Our findings may be
extrapolated to the majority of patients receiving corticosteroids in the intensive care
setting.
Although we did not study the effect of giving dexamethasone compared to no
dexamethasone is this study, the first dose of dexamethasone also induced consid-
erable insulin resistance as we have observed in a previous study.18 Withholding of
the dose administrated upon induction of anesthesia could further improve glucose
control around the time of ICU admission. This quantitative study shows that one
should be prepared to administer higher doses of insulin when using dexamethasone
in cardiac surgery patients. In three ICUs in our hospital, we have implemented a
computerized glucose control system. We designed this system so that patients who
receive steroids both get higher initial insulin doses, and are checked more frequently
to promptly detect hyperglycemia.24 Future research on the value of corticosteroids
during cardiac surgery or for other indications in the ICU should pay very close atten-
tion to the hyperglycemic effects of these drugs. If glucose control is not performed
adequately, potential positive effects of steroids could be offset by iatrogenic hyper-
glycemia.
In summary, the administration of dexamethasone exerts a considerable hyper-
glycemic effect in cardiac surgery patients, interfering with glucose control.
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